Bristol-Myers Squibb Company And Gilead Sciences (Foster City, CA) Advance Combo AIDS Treatment

Bristol-Myers Squibb Company (NYSE:BMY) and Gilead Sciences, Inc. (Nasdaq:GILD) today announced they have obtained data supporting bioequivalence of a new formulation of the fixed-dose combination of Bristol-Myers Squibb's Sustiva(R) (efavirenz) and Gilead's Truvada(R) (emtricitabine and tenofovir disoproxil fumarate) with the components that make up the new combination. The new fixed-dose regimen is intended for the treatment of HIV-1 infection in adults. The fixed-dose regimen was developed using a bi-layer technology to co-formulate Sustiva and Truvada as individually formulated layers combined in one tablet. In August of 2005, Gilead announced that the companies were proceeding with the evaluation of three new formulations in parallel, based on bi-layer technology.

Back to news